Control of insulin secretion by mitochondrial fusion
通过线粒体融合控制胰岛素分泌
基本信息
- 批准号:10753730
- 负责人:
- 金额:$ 63.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-23 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAnabolismAreaBeta CellBlood GlucoseCell physiologyCellsCellular biologyCharacteristicsChronic DiseaseDNA copy numberDataDefectDepositionDiabetes MellitusDiabetes preventionDiabetic mouseDynaminEquilibriumEvaluationExhibitsExposure toFailureFunctional disorderGene DosageGlucose IntoleranceGoalsGuanosine Triphosphate PhosphohydrolasesHealthHomeostasisHumanImpairmentInduced MutationInsulinLinkMaintenanceMediatingMembraneMetabolicMitochondriaMitochondrial DNAMitochondrial MatrixMitochondrial RNAModelingNon-Insulin-Dependent Diabetes MellitusPancreasPathogenesisPathway interactionsPatientsPeptide HydrolasesPeripheralPhysiologicalPloidiesPluripotent Stem CellsPower PlantsPrediabetes syndromeProductionPublishingRegulationReportingRespirationRiskRoleSignal TransductionStressStructural defectStructureTestingTissuesXenograft Modelblood glucose regulationdiabetes pathogenesishigh resolution imagingimaging approachimprovedin vivoinsightinsulin secretionisletislet amyloid polypeptidemetabolomicsmitochondrial dysfunctionmitochondrial membranemouse modelnovelnovel therapeuticsoptogeneticsoverexpressionpharmacologicposttranscriptionalpreventrestorationsuperresolution imaging
项目摘要
ABSTRACT
Diabetes results from insufficient functional β-cell mass to meet peripheral insulin demands. β-cells rely upon
mitochondrial respiration to generate the energy necessary for insulin biosynthesis, processing, and secretion.
Indeed, defects in mitochondrial structure and function have been reported in the β-cells of patients with type 2
diabetes (T2D). Defects in mitochondrial structure and function are characteristic of impairments in mitochondrial
dynamics, the balance of fusion and fission of mitochondrial networks. Mitochondrial fusion is governed by
several dynamin-like GTPases, including Mitofusins 1 and 2 (Mfn1 and 2). Expression of Mfn1 and/or Mfn2 are
reduced in human T2D islets, mouse models of T2D, and following the deposition of toxic islet amyloid
polypeptide oligomers. However, the functions of Mfn1 and Mfn2 in β-cells in vivo, and their role in T2D
pathogenesis are unclear. Therefore, our goal is to dissect the mechanistic and physiologic regulation of
mitochondrial fusion in β-cells to elucidate its contribution to diabetes pathogenesis. The central hypothesis to
be tested is that Mfn1 and 2 regulate insulin secretion and islet β-cell connectivity through control of mitochondrial
DNA and network stability, and their dysregulation contribute to β-cell failure in T2D. We will test this hypothesis
by the following approach: Specific Aim 1 will directly assess the mechanistic implications of loss of mitochondrial
fusion on control of mitochondrial DNA copy number. Specific Aim 2 will delineate the mechanisms by which
incretins restore insulin secretion following impairments in mitochondrial fusion. Specific Aim 3 will investigate
the importance of mitofusins within human β-cells. We anticipate obtaining a clear understanding of the
importance and translational relevance of mitochondrial fusion in β-cell function from an evaluation of the central
effectors crucial to the maintenance of mitochondrial structure. These results should advance the field of β-cell
biology by defining the role of mitochondrial fusion in T2D pathogenesis and could open new horizons for
therapies for patients with diabetes.
摘要
糖尿病是由于功能性β细胞质量不足以满足外周胰岛素需求而引起的。β细胞依赖于
线粒体呼吸产生胰岛素生物合成、加工和分泌所需的能量。
事实上,在2型糖尿病患者的β细胞中已经报道了线粒体结构和功能的缺陷。
糖尿病(T2 D)。线粒体结构和功能的缺陷是线粒体损伤的特征。
动力学,线粒体网络融合和裂变的平衡。线粒体融合由
几种动力蛋白样GTP酶,包括线粒体融合蛋白1和2(Mfn 1和2)。Mfn 1和/或Mfn 2的表达是
在人T2 D胰岛、T2 D小鼠模型中以及在毒性胰岛淀粉样蛋白沉积后减少
多肽寡聚体。然而,Mfn 1和Mfn 2在体内β细胞中的功能,以及它们在T2 D中的作用,
发病机制尚不清楚。因此,我们的目标是剖析的机制和生理调节,
图1示出了在β细胞中的线粒体融合以阐明其对糖尿病发病机制的贡献。核心假设是
Mfn 1和2通过控制线粒体膜电位来调节胰岛素分泌和胰岛β细胞连接,
DNA和网络稳定性及其失调导致T2 D中的β细胞衰竭。我们将检验这一假设
具体目标1将直接评估线粒体缺失的机制影响,
融合对线粒体DNA拷贝数的控制。具体目标2将描述
肠促胰岛素在线粒体融合受损后恢复胰岛素分泌。第3章调查
线粒体融合蛋白在人类β细胞中的重要性。我们期待着获得一个清晰的理解,
线粒体融合在β细胞功能中的重要性和翻译相关性,
对维持线粒体结构至关重要的效应子。这些结果将推动β细胞研究领域的发展
生物学通过定义线粒体融合在T2 D发病机制中的作用,可以为
糖尿病患者的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brett A Kaufman其他文献
Brett A Kaufman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brett A Kaufman', 18)}}的其他基金
Developing intrabody therapeutics for mitochondrial DNA heteroplasmy
开发线粒体 DNA 异质性的体内疗法
- 批准号:
10386997 - 财政年份:2022
- 资助金额:
$ 63.79万 - 项目类别:
Developing intrabody therapeutics for mitochondrial DNA heteroplasmy
开发线粒体 DNA 异质性的体内疗法
- 批准号:
10585928 - 财政年份:2022
- 资助金额:
$ 63.79万 - 项目类别:
Mitochondrial G-quadruplex structures in health and disease
健康和疾病中的线粒体 G-四链体结构
- 批准号:
10428535 - 财政年份:2020
- 资助金额:
$ 63.79万 - 项目类别:
Mitochondrial G-quadruplex structures in health and disease
健康和疾病中的线粒体 G-四链体结构
- 批准号:
10221730 - 财政年份:2020
- 资助金额:
$ 63.79万 - 项目类别:
Transduction of Psychological Stress into Systematic Inflammation by Mitochondrial DNA Signaling
通过线粒体 DNA 信号传导将心理压力转变成系统性炎症
- 批准号:
10574523 - 财政年份:2019
- 资助金额:
$ 63.79万 - 项目类别:
Transduction of Psychological Stress into Systematic Inflammation by Mitochondrial DNA Signaling
通过线粒体 DNA 信号传导将心理压力转变成系统性炎症
- 批准号:
9920214 - 财政年份:2019
- 资助金额:
$ 63.79万 - 项目类别:
Transduction of Psychological Stress into Systematic Inflammation by Mitochondrial DNA Signaling
通过线粒体 DNA 信号传导将心理压力转变成系统性炎症
- 批准号:
10359137 - 财政年份:2019
- 资助金额:
$ 63.79万 - 项目类别:
Molecular mechanisms of mitochondrial DNA deletion formation
线粒体DNA缺失形成的分子机制
- 批准号:
9261548 - 财政年份:2015
- 资助金额:
$ 63.79万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 63.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 63.79万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 63.79万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 63.79万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 63.79万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 63.79万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 63.79万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 63.79万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 63.79万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 63.79万 - 项目类别: